Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Moleculin Biotech ( (MBRX) ).
On August 18, 2024, Moleculin Biotech held its 2025 Annual Meeting of Stockholders, where several key proposals were voted on by shareholders. The meeting saw the election of directors, ratification of Grant Thornton LLP as the independent public accountant, and approval of amendments to the equity incentive plan and executive compensation. Additionally, shareholders approved the issuance of shares upon the exercise of certain warrants and an increase in authorized shares of common stock. However, the proposal to eliminate supermajority voting requirements was not approved.
The most recent analyst rating on (MBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Average Trading Volume: 5,411,627
Technical Sentiment Signal: Sell
Current Market Cap: $20.67M
Learn more about MBRX stock on TipRanks’ Stock Analysis page.